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ABSTRACT
Objective: Polycystic ovary syndrome (PCOS) is one of the common endocrine disorders among women of reproductive age with a prevalence of 
approximately 5-10% worldwide. PCOS is a complex genetic disorder caused by several genes and environmental factors. The aim of this study is to 
provide an overview on variations in PCOS-associated genes based on underlying genetics
Methods: Detailed literature screening was performed in PubMed. Manual curation process was adopted to extract the information on PCOS, 
associated genes, mechanism of association, details of the association, significance of association mentioned in the papers were carefully captured 
according to the authors’ interpretation of the results.
Results: The detailed literature study revealed several genes and the genetic variations in PCOS and its critical effects, such as ovarian failure, obesity, 
spontaneous abortion, recurrent pregnancy loss, insulin resistance, and hyperandrogenim. The causal genetic variants were assembled at various 
levels, including mutation, single nucleotide polymorphism, etc., in PCOS and the associated phenotypic effects.
Conclusion: The genetic variations play an important role in the pathogenesis of PCOS across different ethnicities, as it is associated with various other 
endocrine disorders including diabetes, insulin resistance, cardiovascular diseases, hyperandrogenism, reproductive disorders, etc. The underlying 
mechanism and the network help in identifying the candidate genes or biomarkers in the disease conditions.
Keywords: Polycystic ovary syndrome, Gene, Mutation, Polymorphism, Single nucleotide polymorphism.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a complex disorder affecting 
approximately 5-10% of all women of reproductive age [1]. It is a 
multifactorial endocrine disorder, which demonstrates menstrual 
disturbance, infertility, anovulation, hirsutism, and hyperandrogenemia/
hyperandrogenism [2]. PCOS is a common reproductive disorder 
characterized by arrested follicular development prior to selection of 
a dominant follicle. The increase in the secretion of androgens by the 
ovaries and the adrenal glands is one of the pathological effects observed 
in PCOS [3]. PCOS is also associated with an increased risk of developing 
Type 2 diabetes, dyslipidemia, and cardiovascular diseases [4]. Insulin 
resistance, a common disorder associated with PCOS, is as high as up to 
70% in PCOS condition [3]. The etiology of the disease has been difficult 
to determine because of its heterogenousity. The cause of PCOS is still 
unclear; however, it has been observed that various environmental 
and genetic factors, such as genetic variations, differential regulation 
of genes, and affected pathways, may contribute to the pathogenesis of 
PCOS [4]. Women with PCOS are also at an increased risk of developing 
gestational diabetes and pre-term birth (PTB) [5,6]. It has also been 
observed that the pregnant women diagnosed with PCOS are likely 
to give birth to premature babies [5]. Although various studies have 
been performed on PCOS, the information is scattered in the literature, 
which is the most specific challenge for researchers. Our earlier study 
presented an overview of the differential regulation of genes in PCOS 
including miRNAs and its influence in causing various phenotypic 
changes associated with PCOS [7].
In this paper, we have assembled the information on genetic variations 
in PCOS and its uniqueness to different population or ethnicities, 
through comprehensive literature study. Based on the detailed 
literature curation, we have collected information on several susceptible 
genes and its variations in PCOS condition. Both significant and non-
significant association of variations in PCOS, along with conflicting 
data and negative correlation, have been covered in this paper. We have 
underpinned the critical genetic variations in PCOS across different 
ethnicities and its associated effects, such as endometrial receptivity, 
implantation failure, recurrent pregnancy loss (RPL), early pregnancy 




“PCOS” or “polycystic ovary syndrome” and “gene” and “mutation or 
polymorphism or variation or single nucleotide polymorphisms (SNP)” 
were used as keywords in PubMed Medline database to search for 
the research papers. References were screened at the abstract level 
to segregate the false positive papers from the hit list. All potential 
published studies on candidate genes and PCOS were identified 
through different databases and evaluated. The true positive papers 
were collected to perform the manual data extraction process.
Data extraction
Manual curation process was adopted to extract the information. All 
papers were read, and specific information on PCOS, associated genes, 
mechanism of association, details of the association, significance of 
association mentioned in the papers were carefully captured according 
to the authors’ interpretation of the results.
RESULTS AND DISCUSSION
Genetic variations in PCOS
AdiponectinQ (ADIPOQ)
ADIPOQ (adiponectin, C1Q, and collagen domain containing) is a protein-
coding gene. Research based on the relationship between the variation 
of the two SNPs (rs2241766 and rs1501299) in the adiponectin gene 
and PCOS has revealed ADIPOQ rs2241766 polymorphism as a marker 
for high susceptibility to PCOS [9], and additional study has concluded 
that adiponectin gene variant SNP rs1501299 is considerably linked 
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to the threat for PCOS in the Chinese Han population [10]. T45G 
polymorphisms in the adiponectin gene are of high prevalence in PCOS 
patients compared to controls [11]. The variation of the SNP 45T/G 
and 276G/T in the adiponectin gene is linked to susceptibility to PCOS 
and may be associated with high blood pressure in PCOS [12]. The 
variation of the two SNPs in exon 2 and intron 2 in the adiponectin gene 
is associated with the susceptibility to PCOS in Caucasian women [13]. 
There are studies that did not reveal a strong association of the SNP 
45T/G and 276G/T to PCOS; however, an interaction between the 
ADIPOQ and steroid action was observed by Xian [14].
Androgen receptor (AR)
ARs (also known as dihydrotestosterone receptors) are nuclear 
hormone receptors. Studies based on the investigation of the AR 
encoded by an increasingly polymorphic CAG trinucleotide repeat 
tract in PCOS revealed that there is an association between short CAG 
repeat length and the pathological process of polycystic ovaries in 
PCOS patients of Indian and Chinese population [15]. AR (CAG) n gene 
and its differential methylation patterns influence the progression of 
the disease leading to PCOS in Australian Caucasian women [16]; the 
variation influences the testosterone effects on insulin resistance in 
PCOS women [17]. It is also found that the CAG trinucleotide repeat 
polymorphism increases the susceptibility to PCOS, either by increasing 
the AR activity or by triggering hyperandrogenism [18]. Polymorphism 
of the AR gene is likely a biomarker for PCOS [19]. In a contradictory 
note, few studies revealed that the CAG length variations in AR gene 
were not associated with PCOS, though there was a negligible over-
representation of short CAG alleles in some cases [20,21].
Calpain-10 (CAPN10)
CAPN10 is a protein-coding gene. It represents a ubiquitous, 
well-conserved family of calcium-dependent cysteine proteases. 
Investigations based on the CAPN10 gene and its association with 
the etiology of PCOS revealed that the CAPN10 UCSNP-44 allele 
polymorphism is related to PCOS in the Spanish population [22], linked 
with the manifestation of PCOS in the South Indian population [23]. 
In addition, novel candidate risk alleles and genotypes are accredited 
within CAPN10 gene which could be linked to significant phenotypic 
and diagnostic differences observed in PCOS patients [24]. The etiology 
of PCOS revealed that the CAPN10 UCSNP-63 allele polymorphism 
is related to PCOS; moreover, recessive model and an insertion 
allele of UCSNP-19 are defensive factors, while deletion allele and 
heterozygous genotype are threat factors for the development of 
PCOS [25]. Another study has concluded that UCSNP-19, UCSNP-63, 
and UCSNP-45 polymorphisms might be the threat factors for PCOS, 
particularly among the Asian population [26]. A study on the variation 
of the 112/121-haplotype of the CAPN10 gene has concluded that the 
112/121-haplotype combination is linked with the high risk of PCOS in 
both African American and White population [27]. On a contradictory 
note, a couple of studies have ruled out the association of SNP-43, 44, 
19, 45 of the CAPN10 gene in PCOS [11,28].
Cytochrome P450 genes (CYPs) in PCOS
CYP genes encode the cytochrome P450 superfamily of enzymes. 
A study on the association of CYP21 gene mutations revealed that the 
heterozygosity for 21-hydroxylase deficiency (21-OHD) may be related 
to functional adolescent hyperandrogenism and premature adrenarche; 
however, further studies are vital to conclude whether heterozygosity 
for 21-OHD envisages the risk for PCOS [29]. The evaluation of the 
incidence of heterozygosity for adrenal 21-OHD in patients with 
true precocious puberty revealed a high incidence of heterozygosity 
for adrenal steroid 21-OHD; these patients have to be monitored 
continuously as they might develop PCOS in the later stages [30]. The 
study involving CYP21 mutation carriers showed that 21-hydroxylase 
(CYP21) nonsense mutation carriers were non-indicative, whereas 
the missense mutation carriers that is V281L appeared to mark a 
PCOS phenotype [31]. Late-onset congenital adrenal hyperplasia 
(LOCAH) occurs due to 2l-hydroxylase (21-OH) deficiency and is 
found to be associated with the major histocompatibility complex in 
hirsutism and polycystic ovary in Turkish women; V281L mutation 
was the most common mutation found in these patients which 
confirm that LOCAH is linked to the histocompatibility complex [32]. 
Mutations in CYP21 gene and insulin receptor substrate-1 (IRS1) 
gene variant G972R possibly increase the risk of evolving adrenal 
androgen (AA) excess in PCOS. However, these mutations seem to 
play a restricted role in the development of PCOS [33]. Investigations 
have showed that polymorphism in the regulatory region of CYP11a 
is linked to PCOS [34]. Studies based on the association of the (tttta)n 
polymorphism of the promoter region of CYP11A gene and PCOS have 
inferred that there is an association between CYP11A polymorphism 
and the pathological process of PCOS in Chinese women [35,36]. There 
have been various studies that revealed a negative correlation of (tttta)
(n) repeat polymorphism with PCOS; the results inferred that the (tttta)
(n) repeat polymorphism in the promoter region of CYP11a does not 
play a significant role in these diseases in Spanish [37] and Chinese 
women [38].
Studies based on the association of CYP19(TTTA)n polymorphism 
with the hormonal profile of PCOS inferred that there is a possible 
association of CYP19(TTTA)7 allele with the abetted reproduction 
outcome in PCOS patients [39]. SNPs of the aromatase (CYP 19) gene 
and PCOS have suggested that the variation in this gene is linked to 
the androgen excess in girls and young women [40]. Contradictory 
results were published stating that there was no significant association 
between (TTTA)n polymorphism in intron 4 of CYP19 gene and PCOS in 
Chinese women [41].
Studies based on the relationship between T→C substitution (−34 bp) 
of CYP17 gene promoter and the pathological process of PCOS have 
suggested that this base pair substitution is not the prime hereditary 
defect in PCOS, but it might exacerbate hyperandrogenemia, especially 
when homozygosity exists [42,43]. Investigations based on the 
association between −344T polymorphism in aldosterone synthetase 
(CYP11B2) gene promoter region and the pathological process of 
PCOS have suggested that the −344T polymorphism site of CYP11B2 
gene is associated with high risk of PCOS, and that −344CC and −344TC 
may be the predisposed genotype of PCOS [44]. Studies based on 
the relationship between CYP1A1 rs4646903 (T>C) polymorphism 
and the susceptibility to PCOS have inferred that CYP1A1 rs4646903 
(T>C) polymorphism may support an increased susceptibility to PCOS, 
particularly among Turkish and Indian women [45].
Serpin peptidase inhibitor (SERPINE1)
SERPINE1 (clade E [nexin, plasminogen activator inhibitor [PAI] 
Type 1], member 1) is a protein-coding gene. PAI-Fx is known to 
be the self-determining risk factor for miscarriage in PCOS and 
studies based on this have proved that PAI-Fx is a key reversible risk 
factor for miscarriage in women with PCOS [46]. Studies based on 
the relationship between the variation of the 4G/5G polymorphism 
of PAI-1 gene and PCOS have concluded that this polymorphism is 
associated with PCOS and in addition it increases the PAI-1 levels in 
PCOS patients [47], and it also concluded that 4G/6G polymorphism 
is associated with PCOS in Chinese women and particularly in non-
obese PCOS patients and those with spontaneous miscarriage [48]. The 
variation of the 4G/5G polymorphism of PAI-1 gene has concluded that 
high PAI-1 levels seem to be linked with first-trimester miscarriage in 
PCOS women [49]; in addition, the 4G/5G variation increases the PAI-1 
levels which are positively linked with the proinflammatory factors in 
PCOS patients [50].
Transcription factor-7-like 2 (TCF7L2)
TCF7L2 (T-cell specific, HMG-box) is a protein-coding gene. Studies 
based on the association between the variation in TCF7L2 locus 
(rs11196236 G) and PCOS have suggested that this polymorphism is 
linked with the peripheral insulin (INS) resistance in PCOS in European 
population [51]. It has been found that SNPs rs11196218 and rs290487 
of the TCF7L2 gene are linked with a high threat for early impairment of 
glucose homeostasis in PCOS in Chinese women [52]. On a contradictory 
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note, it is being found that rs11196236 C/T in the TCF7L2 gene are not 
associated with PCOS in Southern Brazilian women [53].
Factor leiden V (F5)
F5 (coagulation factor V [proaccelerin, labile facto]) is a protein-coding 
gene, which encodes an important cofactor of the blood coagulation 
process. Factor V Leiden mutation is one of the causes for RPL and 
spontaneous abortion in PCOS patients. Studies have proved that the 
thrombophilic G1691A Factor V Leiden mutation is linked with RPL in 
women both with and without PCOS in the Caucasian population [54]. 
Administration of enoxaparin metformin leads to a reduction of 
pregnancy loss in patients with one or more prior spontaneous abortion 
along with thrombophilia and/or hypofibrinolysis [55].
INS
INS is a protein-coding gene. Investigations have showed that INS-
variable number tandem repeat (VNTR) (the minisatellite in the 
regulatory region of the INS gene) is linked to PCOS [34]. Allelic variation 
of the INS VNTR gene is found to be associated with the pulsatility of 
INS secretion in PCOS [34]. INS gene VNTR polymorphism is linked with 
the etiology of PCOS in UK women [56]. Few studies reported that the 
INS VNTR gene polymorphism is not correlated with PCOS [57-60].
Insulin receptor (INSR)
INSR is a tyrosine kinase, which regulates the pleiotropic activities of 
insulin. Novel heterozygous mutation in exon 19 (His1130Arg) of INSR 
gene is found to have an association with the progression of PCOS [61]. 
A study on the polymorphism in exon 17 of the INSR gene and PCOS 
has revealed that this polymorphism is linked to an increased risk of 
insulin resistance in women with PCOS [62], and exon 17 C/T, 1058 
site nucleotide polymorphism is linked with susceptibility to PCOS in 
lean subjects [63,64]. His 1058 C/T SNP found in exon 17 in the INSR 
gene is linked with the pathological process of PCOS in non-obese 
Japanese patients [65]. T/C SNP at codon Cys1008 (position 3128 of 
NM_000208) of INSR gene is linked with decreased insulin sensitivity 
in PCOS in Chinese women [66].
IRS
IRS 1 and 2 mediate the control of various cellular processes by insulin. 
Gly972Arg in the IRS-1 gene plays a functional role in the insulin-
resistant component of PCOS [67] and found to be linked with the 
pathogenesis of the metabolic element of PCOS [68]. Studies based on 
the relationship between the variation of G972R in the IRS-1 gene and 
PCOS along with AA excess have concluded that this polymorphism is 
linked with the development of PCOS to a limited extent in non-Hispanic 
white women with PCOS [33]. On a contradictory note, several studies 
have concluded that the polymorphism Gly972Arg in the IRS-1 gene is 
not common and is not associated with PCOS [69] in Taiwanese [11], 
Croatian [60], and Spaniard [70] women.
Research based on the relationship between the variation of 
Gly1057Asp IRS-2 gene and PCOS has concluded that this polymorphism 
manipulates the blood sugar levels in non-diabetic white or African 
American women with PCOS; in addition, people with IRS-2 Gly/Gly 
genotype may develop Type 2 diabetes in the later stages [71], and the 
polymorphism Gly1057Asp of IRS-2 gene might play a functional role 
on the insulin-resistant component of PCOS [67].
Luteinizing hormone beta-subunit (LHB)
LHB polypeptide is a protein-coding gene. It promotes ovulation by 
stimulating the ovaries to synthesize steroids. A study was conducted to 
determine the relationship between LH-beta subunit mutations (Trp8 
to Arg8 and Ile15 to Thr15 in the LH beta subunit gene) and PCOS in 
women. The results revealed that these mutations were considerably 
associated with PCOS [72]; the presence of these mutations may help to 
diagnose the threat for PCOS particularly in obese women [73]. Further 
study on the point mutations (nucleotide mutations within codons 8 
and 15 in the LH beta-subunit gene) in British population revealed 
that the incidence was not higher in women with PCOS, though it 
was increased in obese women with PCOS [74]. Studies based on the 
association between the rs1056917 variant of the luteinizing hormone 
β-subunit gene and PCOS have suggested that this polymorphism is not 
of much significance with PCOS in south Indian women [75].
LH/choriogonadotropin receptor (LHCGR)
LHCGR is a protein-coding gene. An investigation on S312N 
polymorphism of the LHCGR gene revealed that this variant is strongly 
linked with PCOS in the Sardinian population [76]. The association 
of rs13405728 variant in the LHCGR gene and PCOS was found in 
Caucasian patients of Danish origin [77] and have suggested that the 
gene products of the LHCGR gene is linked with the diagnosis of PCOS, 
despite ethnicity [78,79].
Peroxisome proliferator-activated receptor (PPAR)-gamma2 
(PPARG)
PPARG is a protein-coding gene. This gene encodes a member of the 
PPAR subfamily of nuclear receptors. Studies based on the relationship 
between the variation of the Pro(12)Ala polymorphism in PPARG gene 
and PCOS have concluded that this polymorphism is linked with the 
alterations in insulin resistance in Caucasian women with PCOS [80] and 
has concluded that this polymorphism is linked with the pathological 
process of PCOS [81], high insulin sensitivity in PCOS [82], and might 
act as a modifier of insulin resistance in patients with PCOS [83], and 
manipulate the insulin resistance in Indian women with PCOS [84]. 
The C→T substitution in exon 6 of the PPARG gene is linked with the 
pathological process (obesity) of PCOS [85].
Follicle-stimulating hormone receptor (FSHR)
FSHR is a protein-coding gene. It is the receptor for Follicle-stimulating 
hormone and functions in gonad development. The single nucleotide 
polymorphsim (rs1922476) in FSH receptor gene is linked to the cause 
or reason for PCOS in Chinese and Europen population, and the variation 
is possibly important in PCOS irrespective of the ethnicities [78]. 
Several studies related to the association of FSHR and PCOS have 
revealed negative correlation. A study was conducted to search for any 
mutations in the FSHR gene with two known polymorphisms, namely 
Thr307Ala and Ser680Asn, and its association with PCOS. However, not 
a single mutation could be identified in the entire coding region of the 
FSHR gene. Hence, it appears that this gene is not the cause for PCOS in 
Chinese Singapore women [86]. Investigations based on the relationship 
between FSHR p. Asn680Ser polymorphism and PCOS have revealed 
that there is no association between FSHR p. Asn680Ser polymorphism 
and PCOS in women [87]. Studies based on the relationship between 
FSHR Ala307Thr and Ser680Asn polymorphisms and PCOS have 
revealed that both these variants are not a cause for PCOS in Northern 
Chinese Han women [88].
CONCLUSION AND FUTURE PERSPECTIVES
In summary, although the etiology of PCOS is still unclear, the pathology 
of PCOS can be associated with the macro and micro environmental 
factors. The genetic variations play an important role in the pathogenesis 
of PCOS across different ethnicities, as it is associated with various 
other endocrine disorders including diabetes, insulin resistance, 
cardiovascular diseases, hyperandrogenism, reproductive disorders, 
etc. The underlying mechanism and the network help in identifying the 
candidate genes or biomarkers in the disease conditions. The next step 
of this research is to publish the results to the scientific community in 
the form of searchable relational database.
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